Trial Profile
The SCaIPEL study: Survival and Quality of Life of Cancer Patients with Incidental Pulmonary Embolism Treated with LMWH
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 13 May 2019
Price :
$35
*
At a glance
- Drugs Dalteparin sodium (Primary)
- Indications Pulmonary embolism
- Focus Therapeutic Use
- Acronyms SCaIPEL
- 12 May 2019 Status changed from recruiting to discontinued.
- 09 Oct 2015 New trial record